You are here: Industry Insights > NSCLC

News List

FDA Approves TEPMETKO for Metastatic Non-Small Cell Lung Cancer americanpharmaceuticalreview
February 10, 2021
The U.S. Food and Drug Administration (FDA) approved TEPMETKO (tepotinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymalepithelial transition (MET) exon 14 skipping alterations.
FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC americanpharmaceuticalreview
February 09, 2021
The U.S. Food and Drug Administration (FDA) granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping ...
Keytruda recommended for routine NHS use in lung cancer pharmatimes
February 05, 2021
MSD’s immunotherapy Keytruda (pembrolizumab) has gained a NICE recommendation for NHS England routine commissioning for the first-line treatment of non-small cell lung cancer (NSCLC).
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations prnasia
February 04, 2021
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has approved TEPMETKO® (tepotinib) following Priority Review for the treatment of adult patients with metastatic non-small cell lung cancer ...
Sotorasib shows success against non-small cell lung cancer in Phase II trial europeanpharmaceuticalreview
February 01, 2021
In a Phase II trial, sotorasib was shown to be effective against pre-treated non-small cell lung cancer (NSCLC).
AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early trials pharmatimes
January 29, 2021
AstraZeneca (AZ) and Daiichi Sankyo have posted new data from Phase I/II trials evaluating their respective antibody drug conjugates (ADCs) Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan.
CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in Chinese Patients with Advanced RET Fusion-positive Non-Small Cell Lung Cancer after Platinum-based Chemot prnasia
January 28, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today announced that results from a cohort of Chinese patients in the global ...
Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer pharmaceutical-business-review
January 20, 2021
New option extends dosing from two to four weeks, reducing medical visits and improving patient convenience.
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer prnasia
January 12, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced with Eli Lilly and ...
Roche gets FDA breakthrough therapy status for tiragolumab plus Tecentriq pharmaceutical-business-review
January 08, 2021
Roche has secured a breakthrough therapy designation from the US Food and Drug Administration (FDA) for tiragolumab plus Tecentriq (atezolizumab) to treat PD-L1-high non-small cell lung cancer (NSCLC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page